DDInter1765 DDInter1435
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Teniposide {u} (Compound) resembles {v} (Compound) Podofilox
Teniposide {u} (Compound) treats {v} (Disease) lung cancer
Teniposide {u} (Compound) binds {v} (Gene) CYP2C9
Teniposide {u} (Compound) upregulates {v} (Gene) EDEM1
Teniposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Teniposide {u} (Compound) downregulates {v} (Gene) CLTC
Teniposide {u} (Compound) causes {v} (Side Effect) Flushing
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Teniposide (Compound) resembles Podofilox (Compound)
Teniposide (Compound) treats lung cancer (Disease)
Teniposide (Compound) binds CYP2C9 (Gene)
Teniposide (Compound) upregulates EDEM1 (Gene)
Teniposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Teniposide (Compound) downregulates CLTC (Gene)
Teniposide (Compound) causes Flushing (Side Effect)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Delavirdine
Teniposide may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa